MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
MediWound Ltd. (MDWD) will release its financial results for Q4 and full year 2023 on March 21, 2024. A conference call and webcast will follow to discuss the results and provide updates.
03/14/2024 - 08:00 AM
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time
YAVNE, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, March 21, 2024.
Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions.
Dial-in and call details are as follows:
Conference Call & Webcast Details Toll-Free: 1-833-630-1956 Israel: 1-80-921-2373 International: 1-412-317-1837 Webcast: Click HERE
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. MediWound specializes in the development, production and commercialization of solutions that seek to improve existing standards of care. The Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid® , is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company’s lead drug under development, EscharEx® . EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant potential advantages over the $360 million dominant product and an opportunity to expand the market. MediWound’s pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a Phase I/II study.
For more information visit www.mediwound.com and follow the Company on LinkedIn and X .
When will MediWound Ltd. release its financial results for Q4 and full year 2023?
MediWound Ltd. will release its financial results for Q4 and full year 2023 on March 21, 2024.
What is the ticker symbol for MediWound Ltd.?
The ticker symbol for MediWound Ltd. is MDWD.
When is the conference call and webcast scheduled?
The conference call and webcast are scheduled for Thursday, March 21st at 8:30 am Eastern Time.
How can participants access the conference call and webcast?
Participants can access the call by dialing the provided telephone numbers at least 5 minutes before the start of the call.
Where can participants find the archived version of the webcast?
The archived version of the webcast will be available for replay on the Investors section of the MediWound website.
MDWD Rankings
#3123 Ranked by Stock Gains
MDWD Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
Israel
City
42 Hayarkon Street
About MDWD
mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. mediwound’s first innovative biopharmaceutical product, nexobrid®, received marketing authorization from the european medicines agency as well as the israeli and argentinian ministries of health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in europe israel and argentina. nexobrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue. mediwound's second innovative product, escharex®, is a topical biological drug being developed for debridement of chronic and